CAMBRIDGE, Mass., March 29 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that Eric Pauwels will join the
company as Senior Vice President, Global Commercial Operations effective April
13, 2005. In this position, Mr. Pauwels will have overall responsibility for
TKT's worldwide commercialization initiatives, including the potential launch
of iduronate-2-sulfatase (I2S) for Hunter syndrome and ongoing marketing
efforts for Replagal(TM), TKT's enzyme replacement therapy for Fabry disease.
In addition, Mr. Pauwels will provide commercial input on the prioritization
and value of TKT's emerging new product pipeline.
"Eric joins TKT at an exciting time as we prepare to expand our marketing
and sales efforts and introduce new products to the marketplace," said David
D. Pendergast, Ph.D., Executive Vice President and Chief Operating Officer of
TKT. "With nearly twenty years of commercial pharmaceutical experience, Eric
has successfully led marketing and sales activities in the United States,
Europe and Asia. Eric will play a significant role in expanding TKT's
commercial expertise and will provide strong direction to TKT as we execute on
new initiatives, including our anticipated first commercial U.S. launch in
2006."
Mr. Pauwels joins TKT from Bayer Healthcare Pharmaceuticals where he most
recently managed the global commercialization for LEVITRA(R) for erectile
dysfunction in his role as Vice President Global Strategic Marketing, Men's
Health. Previously, he was Vice President Global Strategic Marketing,
Cardiovascular at Bayer and held several positions of increasing
responsibility in sales and marketing at Laboratories Fournier for more than
four years. Mr. Pauwels has also held marketing and sales positions at Janssen
Pharmaceutica Products and McNeil Pharmaceuticals where he managed several
product launches, including RISPERDAL(R) for psychotic disorders. He received
a B.Sc. from California State Polytechnic University, Pomona.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including whether TKT
will successfully manage its marketing and sales operations; the impact of
competing products on Replagal; whether the FDA and equivalent regulatory
authorities will approve I2S on a timely basis, or at all; and other factors
set forth under the caption "Certain Factors That May Affect Future Results"
in the company's Annual Report on Form 10-K for the year ended December 31,
2004, which is on file with the Securities and Exchange Commission and are
incorporated herein by reference. While the company may elect to update
forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, even if its expectations
change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA. LEVITRA(R) is a registered trademark of Bayer Healthcare
Pharmaceuticals and RISPERDAL(R) is a registered trademark of Janssen
Pharmaceutica Products, L.P.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Manager, Corporate Communications
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Justine E. Koenigsberg, Senior Director,
Corporate Communications, +1-617-349-0271, or Daniella M. Lutz,
Manager, Corporate Communications, +1-617-349-0205, both of
Transkaryotic Therapies, Inc.
|
